Global Heart Attack Diagnostics Market Size study & Forecast, by Test (Electrocardiogram, Blood Tests, Angiogram, Computerized Cardiac Tomography, and Other Tests), End User (Hospitals, Ambulatory Surgical Centers, Diagnostics Centers, and Other End Users

Global Heart Attack Diagnostics Market Size study & Forecast, by Test (Electrocardiogram, Blood Tests, Angiogram, Computerized Cardiac Tomography, and Other Tests), End User (Hospitals, Ambulatory Surgical Centers, Diagnostics Centers, and Other End Users), and Regional Analysis, 2023-2030

Global Heart Attack Diagnostics Market is valued approximately at USD XX billion in 2022 and is anticipated to grow with a growth rate of more than 7.9% over the forecast period 2023-2030. The prevalence of chronic illnesses such as diabetes and hypertension is growing. Numerous risk factors, including as a high body mass index, a change to an unhealthy lifestyle, and cigarette use, will promote atherosclerosis and constrict the coronary arteries as a result of fat deposition and high cholesterol levels. The market growth is driven by key factors such as increase in cases of coronary heart disease, rising obesity and tobacco smoking and increase in healthcare expenditure.

According to a World Health Organization report, cardiovascular disorders including heart attacks and strokes contribute to four out of every five fatalities globally and are the leading cause of mortality. Furthermore, heart attacks and strokes account for 85% of the roughly 13 million fatalities that take place each year in low- and middle-income nations. According to an American Heart Association estimate, 45% of Americans might have some form of heart illness (mostly a heart attack) by 2035, which could be a significant market driver for heart attack diagnostics. Also, according to the findings of a comprehensive survey conducted nationwide in India, approximately 14 percent of male respondents experienced cholesterol issues in 2020. Among female respondents, nearly ten percent reported cholesterol problems, whereas only three percent reported heart problems. Furthermore, higher cost of diagnostic products and increasing R & D, launches of novel developed devices create lucrative opportunities in the forecast years. However, low Medicare reimbursement and higher cost of diagnostic products stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Heart Attack Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is leading the global market share owing to increase in obesity rate in United States and rising number of heart patients in the region. However, Asia Pacific is expected to be the fastest growing region due to increase in healthcare expenditure and technological advancements in diagnosis.


Major market player included in this report are:
Astrazenca PLC
GE Healthcare
Hitachi Corporation
Koninklijke Philips NV
Midmark Corporation
F Hoffmann-La Roche Ltd
Schiller AG
Siemens Healthineers
Toshiba Corporation
Welch Allyn Inc.


Recent Developments in the Market:
 In April 2021, Roche introduced the highly sensitive cardiac troponin T test (cTnT-hs) and the N-terminal pro-brain natriuretic peptide test (NT-proBNP) are two important cardiac biomarkers.
 In March 2021, European Union certified CaRi-Heart Technology, which uses artificial intelligence to identify and predict the danger of a serious heart attack years before it occurs. British Heart Foundation and Caristo Diagnostics collaborated to create the CaRi-Heart Technology.

Global Heart Attack Diagnostics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered – Test, End-User, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Test:
Electrocardiogram
Blood Tests
Angiogram
Computarized Cardiac Tomography
Other Test
By End-user:
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
Other End Users
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Companies Mentioned
Astrazenca PLC
GE Healthcare
Hitachi Corporation
Koninklijke Philips NV
Midmark Corporation
F Hoffmann-La Roche Ltd
Schiller AG
Siemens Healthineers
Toshiba Corporation
Welch Allyn Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.